We upgrade our rating on Thoratec Corporation (NasdaqGS:THOR - News) to Outperform. Its third quarter earnings beat the Zacks Consensus Estimate while profit surged year over year, helped by higher ...

Here at The Motley Fool, I've long cautioned investors to keep a close eye on inventory levels. It's a part of my standard diligence when searching for the market's best stocks. I think a quarterly ...

Thoratec Corp THOR recently announced that the HeartMate III CE mark trial has successfully met its primary endpoint. HeartMate III is a next-generation continuous-flow left ventricular assist device ...

When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." ...

Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measure of a company's economic output. That's because earnings are very often less ...

PLEASANTON, Calif., Oct. 11, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support (MCS) therapies to save, support and restore ...

Here at The Motley Fool, I've long cautioned investors to keep a close eye on inventory levels. It's a part of my standard diligence when searching for the market's best stocks. I think a quarterly ...

BANGALORE, Feb 13 (Reuters) - Cardiac-device maker Thoratec will buy Australia's HeartWare International for about $282 million in a cash and stock deal, which could give Thoratec a stronghold over ...

Thoratec Corp.THOR recently announced the start of patient enrollment in the SHIELD II U.S. clinical trial, which aims at exploring the use of HeartMate PHP in patients undergoing high-risk ...

Thoratec Corp. has named D. Keith Grossman as president and CEO. The appointment is effective immediately. Grossman succeeds Gary F. Burbach, who will remain as an advisor to the company through the ...

Investors eyeing a purchase of Thoratec Corp. (NASD: THOR) shares, but tentative about paying the going market price of $33.13/share, might benefit from considering selling puts among the alternative ...

Thoratec Corporation today issued an urgent safety advisory about a serious problem with a key component of the HeartMate II LVAS system. The company said 4 patients had died and 5 patients had a loss ...